FDA Approves Tibsovo for IDH1-Mutated AML Uncategorized FDA Approves Tibsovo for IDH1-Mutated AML Amelie May 26, 2022 Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly...Read More